A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Medicine, Molecular Genetics, Oncology +17

Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

Zhengui Xia, Martin Dickens, Joël Raingeaud et al. · Science · 1995 · 5.3K citations

Life Sciences, Neurobiology, Neuroscience +16

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

Life Sciences, Molecular Biology, Oncology +13